Subject(s)

Antineoplastic Agents/therapeutic use , Gene Expression Regulation, Neoplastic , Immunoglobulin Heavy Chains/genetics , Integrin alpha4/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Receptors, CXCR4/genetics , Adenine/analogs & derivatives , Agammaglobulinaemia Tyrosine Kinase , Antibodies, Monoclonal, Humanized/therapeutic use , Benzylamines , Chemokine CXCL12/genetics , Chemokine CXCL12/metabolism , Class I Phosphatidylinositol 3-Kinases/antagonists & inhibitors , Class I Phosphatidylinositol 3-Kinases/genetics , Class I Phosphatidylinositol 3-Kinases/metabolism , Cyclams , Genetic Heterogeneity , Heterocyclic Compounds/therapeutic use , Humans , Immunoglobulin Heavy Chains/metabolism , Integrin alpha4/metabolism , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/mortality , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Mutation , Natalizumab , Piperidines , Prognosis , Protein-Tyrosine Kinases/antagonists & inhibitors , Protein-Tyrosine Kinases/genetics , Protein-Tyrosine Kinases/metabolism , Purines/therapeutic use , Pyrazoles/therapeutic use , Pyrimidines/therapeutic use , Quinazolinones/therapeutic use , Receptors, CXCR4/antagonists & inhibitors , Receptors, CXCR4/metabolism , Signal Transduction , Survival Analysis